Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study
Natasha L. Mason, Attila Szabó, Kim P. C. Kuypers, et al.
Brain Behavior and Immunity (2023) Vol. 114, pp. 299-310
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin
Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 2, pp. e121-e132
Closed Access | Times Cited: 9
Psilocybin for the treatment of Alzheimer’s disease
Siyi Zheng, Rong Ma, Yang Yang, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 7
High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin
Dotan Braun, Ayelet M Rosenberg, Elad Rabaniam, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 4, pp. 1046-1062
Open Access | Times Cited: 6
Therapeutic modulation of the kynurenine pathway in severe mental illness and comorbidities: A potential role for serotonergic psychedelics
Antonella Campanale, Antonio Inserra, Stefano Comai
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 134, pp. 111058-111058
Open Access | Times Cited: 6
Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights
Salma Laabi, Claire LeMmon, Callie Vogel, et al.
International Immunopharmacology (2024) Vol. 130, pp. 111753-111753
Closed Access | Times Cited: 5
Making Sense of Psychedelics in the CNS
Blake A. Fordyce, Bryan L. Roth
The International Journal of Neuropsychopharmacology (2024) Vol. 27, Iss. 2
Open Access | Times Cited: 4
Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases
Zarah R. Haniff, Mariia Bocharova, Tim Mantingh, et al.
Pharmacology & Therapeutics (2024) Vol. 258, pp. 108641-108641
Open Access | Times Cited: 4
Early psilocybin intervention alleviates behavioral despair and cognitive impairment in stressed Wistar rats
Zitong Wang, Brett Robbins, R. L. Zhuang, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111243-111243
Open Access
Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers
Juliana Lima Constantino, Jens H. van Dalfsen, Sara Massetti, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025) Vol. 136, pp. 111251-111251
Open Access
Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights
I. Craig Henderson, Ronnie Elsaadany, Gabriel Chan, et al.
Current Pain and Headache Reports (2025) Vol. 29, Iss. 1
Closed Access
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity
Daniel A Kinderlehrer
Neuropsychiatric Disease and Treatment (2025) Vol. Volume 21, pp. 141-155
Open Access
Psychedelics in neuroinflammation: Mechanisms and therapeutic potential
Júnia L. de Deus, Juliana Marino Maia, Renato Nery Soriano, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111278-111278
Closed Access
Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or Long COVID): A comprehensive review
Zhen Xuen Brandon Low, Shin Jie Yong, Hayam A Alrasheed, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111279-111279
Closed Access
Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer’s disease comorbidities?
Michael Davidson, Gabriela Dumitrița Stanciu, Jonathan Rabinowitz, et al.
Dialogues in Clinical Neuroscience (2025) Vol. 27, Iss. 1, pp. 1-12
Open Access
The effect of low-dose psilocybin on brain neurotransmission and rat behavior
Agnieszka Bysiek, Adam Wojtas, Izabela Szpręgiel, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111347-111347
Closed Access
Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial
Ellen Bradley, Kimberly Sakai, Gisele Fernandes‐Osterhold, et al.
Neuropsychopharmacology (2025)
Open Access
Psilocin alleviates acute itch in mice: possible involvement of 5-HT2A receptors and kynurenine pathway
Arya Afrooghe, Elham Ahmadi, Ali Lesani, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Exploring Factors Affecting Psychological Flexibility After Psychedelic Experiences
Bruno Roméo, E. Kervadec, Baptiste Fauvel, et al.
Journal of Psychoactive Drugs (2025), pp. 1-12
Closed Access
Neurobiology of the Antidepressant Effects of Serotonergic Psychedelics: A Narrative Review
Noah Chisamore, Erica Kaczmarek, Gia Han Le, et al.
Current Treatment Options in Psychiatry (2024) Vol. 11, Iss. 2, pp. 90-105
Closed Access | Times Cited: 3
Psychotomimetic compensation versus sensitization
Ari Brouwer, Robin Carhart‐Harris, Charles L. Raison
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 3
Inter-individual variability in neural response to low doses of LSD
Nadia R. P. W. Hutten, Conny W.E.M. Quaedflieg, Natasha L. Mason, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Psilocin, the Psychoactive Metabolite of Psilocybin, Modulates Select Neuroimmune Functions of Microglial Cells in a 5-HT2 Receptor-Dependent Manner
Kennedy R. Wiens, Nicole Brooks, Ishvin Riar, et al.
Molecules (2024) Vol. 29, Iss. 21, pp. 5084-5084
Open Access | Times Cited: 3
Roflumilast: Modulating neuroinflammation and improving motor function and depressive symptoms in multiple sclerosis
Zhaowei Wang, Yanxin Zhang, Jiaqing Chai, et al.
Journal of Affective Disorders (2024) Vol. 350, pp. 761-773
Closed Access | Times Cited: 2
Human pluripotent stem cells as a translational toolkit in psychedelic research in vitro
José Alexandre Salerno, Stevens K. Rehen
iScience (2024) Vol. 27, Iss. 5, pp. 109631-109631
Open Access | Times Cited: 2
Psilocybin Reduces Grooming in the SAPAP3 Knockout Mouse Model of Compulsive Behaviour
James J Gattuso, Carey Wilson, Anthony J. Hannan, et al.
Neuropharmacology (2024) Vol. 262, pp. 110202-110202
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top